News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CordenPharma to Acquire Peptisyntha From Solvay SA, Expanding Peptides Custom Synthesis Business



8/28/2013 10:36:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PLANKSTADT, Germany--(BUSINESS WIRE)--International Chemical Investors Group (ICIG) and the Solvay Group have entered into an agreement under which ICIG will acquire Peptisyntha SA, the Brussels, Belgium, based custom manufacturer of peptides for pharmaceutical use. Upon closing of the deal, expected later this fall, Peptisyntha will become a member of ICIG’s CordenPharma platform as its third site offering peptides manufacturing. “With Peptisyntha, we are adding industry-leading liquid phase synthesis capabilities and a team of highly skilled staff. Together with our solid-phase, hybrid synthesis, and development capacities at our sites in Boulder, Colorado, and Liestal, Switzerland, we will be in an excellent position to offer customers the full range of peptide synthesis strategies and services”, says Christian Ewers, Chief Operating Officer of CordenPharma’s API business.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Solvay SA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES